# Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

> **NCT03892096** · — · COMPLETED · sponsor: **Cadex Genomics** · enrollment: 130 (actual)

## Conditions studied

- Metastatic Non-Small Cell Lung Carcinoma
- Metastatic Colorectal Cancer
- Metastatic Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Blood-based cell-free cfDNA qPCR assay

## Key facts

- **NCT ID:** NCT03892096
- **Lead sponsor:** Cadex Genomics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2023-11-15
- **Final completion:** 2024-02-06
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892096, "Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03892096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*